Jerome D. Cohen, MD, FACC, FACP

5/22/02


Click here to start


Table of Contents

Jerome D. Cohen, MD, FACC, FACP

Background and Rationale for OTC Pravachol

Risk is Graded and Continuous Over Broad Range MRFIT (n=361,662)

Significant Proportion of Coronary Events Occur in Individuals with TC 200-240 mg/dl (MRFIT)

NCEP Guidelines - CHD Risk Factors Other Than LDL-C

Rationale for OTC Therapy

Rationale for OTC Therapy

Major Pravastatin Clinical Outcome Trials

WOSCOPS: Baseline Lipids and Outcome

CARE AND LIPID Baseline Lipids and Events*

Indications for Pravachol

Rationale for Pravachol OTC: Safety

PPT Slide

Author: mmedia3